The Food and Drug Administration on Tuesday named a longtime regulator of cancer medicines to lead the agency's drug center, ...

A 26-year FDA scientist and administrator, Pazdur has headed the agency's Oncology Center of Excellence since its creation in ...

The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur ...

Pazdur replaces former Center for Drug Evaluation and Research Director George Tidmarsh, who exited the agency earlier this ...

Both The U.S. Department of Health and Human Services (HHS) and the FDA announced the appointment of Richard Pazdur, M.D., as ...

Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about ...

Ethicist Art Caplan discusses FDA layoffs and their impact on protection of human research subjects in clinical trials.

An investigation by FDA scientists revealed numerous data inaccuracies in reports that data vendor IQVIA provided to the agency, including data on opioid drug products, the agency announced May 16.

As 2026 approaches, now is the time to reflect on the victories from the year and the lessons to be taken moving forward.

Secretary of Health and Human Services Robert F. Kennedy, Jr., recently announced that the U.S. Food and Drug Administration will launch a review of the safety of the abortion pill, mifepristone.

The Food and Drug Administration is investigating how a contracted document management company accidentally made public 75,000 pages of confidential FDA files related to approval of medical devices, ...

FDA sign & Bldg 21 at Entrance PHOTO COURTESY OF COMMONS.WIKIMEDIA.ORG Washington (AP) — Hormone based drugs used to treat ...